Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01072 ...
Drug Name Atazanavir
Molecular Weight 704.8555
Molecular Formula C38H52N6O7
CAS Number 198904-31-3
SMILES COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
External Links
DRUGBANK DB01072
PubChem Compound 148192
PDR 114
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 4.5 - 4.5 - DRUGBANK
Water Solubility 4500.0 mg/L 4-5 mg/ml DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 64.0 % 60-68 % PO, oral; DRUGBANK
C Max 5400.0 ng/ml 5.4±1.4 mcg/ml PO, oral; food; The Pharmacological Basis of Therapeutics
T Max 2.5 h ~2.5 h DRUGBANK
T Max 2.5 h 2.5 h PO, oral; food; The Pharmacological Basis of Therapeutics
Clearance 0.20 L/h/kg 3.4±1.0 ml/min/kg apparent clearance; hydrolysis; normal,healthy; adults; hepatopathy，LD ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.2 L/kg 1.6-2.7 L/kg Apparent volume of distribution; hydrolysis; normal,healthy; adults; The Pharmacological Basis of Therapeutics
Half-life 7.0 h ~7 h elimination half-life; normal,healthy; adults; DRUGBANK
Half-life 7.0 h ~7 h elimination half-life; AIDS,HIV; adults; DRUGBANK
Half-life 12.1 h 12.1 h elimination half-life; hepatopathy，LD; Single dose; DRUGBANK
Half-life 7.9 h 7.9±2.9 h chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Eliminate Route 7.0 % 7 % Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 86.0 % 86 % human, homo sapiens; Plasma Concentration → ; DRUGBANK
Protein Binding 86.0 % 86 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for infants 200.0 mg/day 200 mg/day PO, oral Reyataz atazanavir PDR
Max dose for children 300.0 mg/day 300 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for children 200.0 mg/day 200 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for children 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for children 250.0 mg/day 250 mg/day PO, oral Reyataz atazanavir PDR
Max dose for children 200.0 mg/day 200 mg/day PO, oral Reyataz atazanavir PDR
Max dose for adolescents 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for adolescents 400.0 mg/day 400 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for adolescents 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for adolescents 300.0 mg/day 300 mg/day Capsule, PO, Oral;PO, oral; Reyataz atazanavir PDR
Max dose for adolescents 200.0 mg/day 200 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for adolescents 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for adults 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for adults 400.0 mg/day 400 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for adults 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for geriatric 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR
Max dose for geriatric 400.0 mg/day 400 mg/day Capsule, PO, Oral Reyataz atazanavir PDR
Max dose for geriatric 300.0 mg/day 300 mg/day PO, oral Reyataz atazanavir PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1